Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31098054 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4EALOX15TSHRACMSD | |
| SCHEMBL7931837 | 0.82 | KDM4E (0.61) | KDM4EALOX15TSHRACMSDTDP1 | |
| Acetic Acid SCHEMBL28168133 | 0.82 | KDM4E (0.38) | ALDH1A1KDM4EALOX15TSHRACMSD | |
| SCHEMBL7770340 | 0.81 | AHR (0.49) | ALDH1A1KDM4EALOX15TSHRACMSD | |
| SCHEMBL2767807 | 0.80 | MAPT (0.48) | ALDH1A1KDM4ETSHRIRAK4CYP1A2 | |
| SCHEMBL22639180 | 0.79 | ALDH1A1 (0.41) | ALDH1A1KDM4EALOX15TSHRACMSD | |
| SCHEMBL882682 | 0.79 | ALDH1A1 (0.38) | ALDH1A1KDM4EALOX15TSHRACMSD | |
| SCHEMBL455687 | 0.79 | KDM4E (0.59) | ALDH1A1KDM4EALOX15TSHRACMSD | |
| SCHEMBL16046267 | 0.78 | ALDH1A1 (0.40) | ALDH1A1KDM4EALOX15TSHRACMSD | |
| SCHEMBL29110703 | 0.78 | ALDH1A1 (0.40) | ALDH1A1KDM4EALOX15TSHRACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034108-A1 | SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2025-01-30 | — | — | US | disclosed |
| US-10828288-B2 | Hydrazone derivatives for the treatment of cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-11-10 | — | — | US | disclosed |
| US-10828288-B2 | Hydrazone derivatives for the treatment of cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180000806-A1 | HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180000806-A1 | HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2016123253-A1 | HYDRAZNE DERIVATIVES FOR THE TREATMENT OF CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123253-A1 | HYDRAZNE DERIVATIVES FOR THE TREATMENT OF CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034108-A1 | SODIUM CHANNEL BLOCKERS | SCN5A, SCN2B, SCN1B | ALDH1A1 2274/4885KDM4E 2742/4885ALOX15 3444/4885 |
| US-20180000806-A1 | HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER | H1-3, H1-5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH1A1 665/4885KDM4E 1330/4885ALOX15 1134/4885 |
| US-10828288-B2 | Hydrazone derivatives for the treatment of cancer | H1-3, H1-5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH1A1 665/4885KDM4E 1330/4885ALOX15 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.